Document is current
Any future updates will be listed below
-
Authors
Mitsuno, Kohei
Suematsu, Masaya
Naito, Yuki
Mayumi, Azusa
Yoshida, Hideki
Osone, Shinya
Imamura, Toshihiko
Nakazawa, Yozo
Yagyu, Shigeki
Iehara, Tomoko
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (22K20832, 22K07825, 20K07641)
- License Information
-
More Information
Article History
Received: 4 August 2024
Accepted: 18 December 2024
First Online: 1 February 2025
Declarations
:
: Shigeki Yagyu is the chief executive officer of A-SEEDS Co., Ltd. with equity, and Yozo Nakazawa is the executive officer of A-SEEDS Co., Ltd. with equity. Masaya Suematsu, Yozo Nakazawa, and Shigeki Yagyu have patent applications in the field of adoptive cell therapy for cancer.
: This study was approved by the Kyoto Prefectural University of Medicine Ethics Committee (Approval No. ERB-C-669 and ERB-C-1406) and conformed to the ethical guidelines of the Declaration of Helsinki and its amendments. All donors provided written informed consent prior to blood sample collection. All animal studies were conducted according to the relevant national and international guidelines. The animal study protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Kyoto Prefectural University of Medicine (Approval No. M2023-47).
: Informed consent was obtained from all individual participants included in the study.
